VEPPANU
Aug 03, 2026
PROTACs: An Emerging Drug Modality with Multiple Oncology Approvals Expected in the Coming Years
Summary PROTACs represent a new modality that eliminates target proteins by leveraging the cell’s ubiquitin-proteasome system. Vepdegestrant (VEPPANU) became the first FDA-approved PROTAC therapy in May 2026 for the treatment of ER+/HER2- ESR1-mutated breast cancer, representing a significant milestone for t...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
